The Experts below are selected from a list of 309 Experts worldwide ranked by ideXlab platform
Simon Tiberi - One of the best experts on this subject based on the ideXlab platform.
-
comparison of effectiveness and safety of imipenem Clavulanate versus meropenem Clavulanate containing regimens in the treatment of mdr and xdr tb
European Respiratory Journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Lia Dambrosio, Rosella Centis, Marcos Abdo Arbex, Edith Alarcon Arrascue, Janwillem C Alffenaar, Jose A Caminero, Mina Gaga, Gina GualanoAbstract:No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/Clavulanate versus meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/Clavulanate versus meropenem/Clavulanate added to background regimens to treat MDR- and XDR-TB cases. 84 patients treated with imipenem/Clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p<0.0001) and higher XDR-TB prevalence (67.9% versus 49.0%, p=0.01) in comparison with 96 patients exposed to meropenem/Clavulanate-containing regimens. Patients were treated with imipenem/Clavulanate- and meropenem/Clavulanate-containing regimens for a median (interquartile range) of 187 (60–428) versus 85 (49–156) days, respectively. Statistically significant differences were observed on sputum smear and culture conversion rates (79.7% versus 94.8%, p=0.02 and 71.9% versus 94.8%, p<0.0001, respectively) and on success rates (59.7% versus 77.5%, p=0.03). Adverse events to imipenem/Clavulanate and meropenem/Clavulanate were reported in 5.4% and 6.5% of cases only. Our study suggests that meropenem/Clavulanate is more effective than imipenem/Clavulanate in treating MDR/XDR-TB patients. Meropenem/Clavulanate is safe and more effective than imipenem/Clavulanate in treating MDR and XDR-TB patients
-
Comparison of effectiveness and safety of imipenem/Clavulanate- versus meropenem/Clavulanate-containing regimens in the treatment of MDR- and XDR-TB
The European respiratory journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Rosella Centis, Marcos Abdo Arbex, Edith Alarcon Arrascue, Janwillem C Alffenaar, Jose A Caminero, Mina Gaga, Lia D'ambrosio, Gina GualanoAbstract:No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/Clavulanate versus meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/Clavulanate versus meropenem/Clavulanate added to background regimens to treat MDR- and XDR-TB cases. 84 patients treated with imipenem/Clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p
-
effectiveness and safety of meropenem Clavulanate containing regimens in the treatment of mdr and xdr tb
European Respiratory Journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Lia Dambrosio, Rosella Centis, Marcos Abdo Arbex, Janwillem C Alffenaar, Jose A Caminero, Mariechristine Payen, Valentina Alarcon Guizado, Saverio De LorenzoAbstract:No large study has ever evaluated the efficacy, safety and tolerability of meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/Clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/Clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/Clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p<0.0001) and the median (interquartile range (IQR)) number of antibiotic resistances was higher (8 (6–9) versus 5 (4–6)). Patients were treated with a meropenem/Clavulanate-containing regimen for a median (IQR) of 85 (49–156) days. No statistically significant differences were observed in the overall MDR-TB cohort and in the subgroups with and without the XDR-TB patients; in particular, sputum smear and culture conversion rates were similar in XDR-TB patients exposed to meropenem/Clavulanate-containing regimens (88.0% versus 100.0%, p=1.00 and 88.0% versus 100.0%, p=1.00, respectively). Only six cases reported adverse events attributable to meropenem/Clavulanate (four of them then restarting treatment). The nondifferent outcomes and bacteriological conversion rate observed in cases who were more severe than controls might imply that meropenem/Clavulanate could be active in treating MDR- and XDR-TB cases. Meropenem/Clavulanate is effective and safe to treat MDR- and XDR-TB in comparison with controls
-
Effectiveness and safety of meropenem/Clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
The European respiratory journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Rosella Centis, Marcos Abdo Arbex, Janwillem C Alffenaar, Jose A Caminero, Lia D'ambrosio, Mariechristine Payen, Valentina Alarcon Guizado, Saverio De LorenzoAbstract:No large study has ever evaluated the efficacy, safety and tolerability of meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/Clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/Clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/Clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p
Gina Gualano - One of the best experts on this subject based on the ideXlab platform.
-
comparison of effectiveness and safety of imipenem Clavulanate versus meropenem Clavulanate containing regimens in the treatment of mdr and xdr tb
European Respiratory Journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Lia Dambrosio, Rosella Centis, Marcos Abdo Arbex, Edith Alarcon Arrascue, Janwillem C Alffenaar, Jose A Caminero, Mina Gaga, Gina GualanoAbstract:No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/Clavulanate versus meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/Clavulanate versus meropenem/Clavulanate added to background regimens to treat MDR- and XDR-TB cases. 84 patients treated with imipenem/Clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p<0.0001) and higher XDR-TB prevalence (67.9% versus 49.0%, p=0.01) in comparison with 96 patients exposed to meropenem/Clavulanate-containing regimens. Patients were treated with imipenem/Clavulanate- and meropenem/Clavulanate-containing regimens for a median (interquartile range) of 187 (60–428) versus 85 (49–156) days, respectively. Statistically significant differences were observed on sputum smear and culture conversion rates (79.7% versus 94.8%, p=0.02 and 71.9% versus 94.8%, p<0.0001, respectively) and on success rates (59.7% versus 77.5%, p=0.03). Adverse events to imipenem/Clavulanate and meropenem/Clavulanate were reported in 5.4% and 6.5% of cases only. Our study suggests that meropenem/Clavulanate is more effective than imipenem/Clavulanate in treating MDR/XDR-TB patients. Meropenem/Clavulanate is safe and more effective than imipenem/Clavulanate in treating MDR and XDR-TB patients
-
Comparison of effectiveness and safety of imipenem/Clavulanate- versus meropenem/Clavulanate-containing regimens in the treatment of MDR- and XDR-TB
The European respiratory journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Rosella Centis, Marcos Abdo Arbex, Edith Alarcon Arrascue, Janwillem C Alffenaar, Jose A Caminero, Mina Gaga, Lia D'ambrosio, Gina GualanoAbstract:No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/Clavulanate versus meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/Clavulanate versus meropenem/Clavulanate added to background regimens to treat MDR- and XDR-TB cases. 84 patients treated with imipenem/Clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p
Giovanni Sotgiu - One of the best experts on this subject based on the ideXlab platform.
-
comparison of effectiveness and safety of imipenem Clavulanate versus meropenem Clavulanate containing regimens in the treatment of mdr and xdr tb
European Respiratory Journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Lia Dambrosio, Rosella Centis, Marcos Abdo Arbex, Edith Alarcon Arrascue, Janwillem C Alffenaar, Jose A Caminero, Mina Gaga, Gina GualanoAbstract:No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/Clavulanate versus meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/Clavulanate versus meropenem/Clavulanate added to background regimens to treat MDR- and XDR-TB cases. 84 patients treated with imipenem/Clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p<0.0001) and higher XDR-TB prevalence (67.9% versus 49.0%, p=0.01) in comparison with 96 patients exposed to meropenem/Clavulanate-containing regimens. Patients were treated with imipenem/Clavulanate- and meropenem/Clavulanate-containing regimens for a median (interquartile range) of 187 (60–428) versus 85 (49–156) days, respectively. Statistically significant differences were observed on sputum smear and culture conversion rates (79.7% versus 94.8%, p=0.02 and 71.9% versus 94.8%, p<0.0001, respectively) and on success rates (59.7% versus 77.5%, p=0.03). Adverse events to imipenem/Clavulanate and meropenem/Clavulanate were reported in 5.4% and 6.5% of cases only. Our study suggests that meropenem/Clavulanate is more effective than imipenem/Clavulanate in treating MDR/XDR-TB patients. Meropenem/Clavulanate is safe and more effective than imipenem/Clavulanate in treating MDR and XDR-TB patients
-
Comparison of effectiveness and safety of imipenem/Clavulanate- versus meropenem/Clavulanate-containing regimens in the treatment of MDR- and XDR-TB
The European respiratory journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Rosella Centis, Marcos Abdo Arbex, Edith Alarcon Arrascue, Janwillem C Alffenaar, Jose A Caminero, Mina Gaga, Lia D'ambrosio, Gina GualanoAbstract:No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/Clavulanate versus meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/Clavulanate versus meropenem/Clavulanate added to background regimens to treat MDR- and XDR-TB cases. 84 patients treated with imipenem/Clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p
-
effectiveness and safety of meropenem Clavulanate containing regimens in the treatment of mdr and xdr tb
European Respiratory Journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Lia Dambrosio, Rosella Centis, Marcos Abdo Arbex, Janwillem C Alffenaar, Jose A Caminero, Mariechristine Payen, Valentina Alarcon Guizado, Saverio De LorenzoAbstract:No large study has ever evaluated the efficacy, safety and tolerability of meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/Clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/Clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/Clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p<0.0001) and the median (interquartile range (IQR)) number of antibiotic resistances was higher (8 (6–9) versus 5 (4–6)). Patients were treated with a meropenem/Clavulanate-containing regimen for a median (IQR) of 85 (49–156) days. No statistically significant differences were observed in the overall MDR-TB cohort and in the subgroups with and without the XDR-TB patients; in particular, sputum smear and culture conversion rates were similar in XDR-TB patients exposed to meropenem/Clavulanate-containing regimens (88.0% versus 100.0%, p=1.00 and 88.0% versus 100.0%, p=1.00, respectively). Only six cases reported adverse events attributable to meropenem/Clavulanate (four of them then restarting treatment). The nondifferent outcomes and bacteriological conversion rate observed in cases who were more severe than controls might imply that meropenem/Clavulanate could be active in treating MDR- and XDR-TB cases. Meropenem/Clavulanate is effective and safe to treat MDR- and XDR-TB in comparison with controls
-
Effectiveness and safety of meropenem/Clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
The European respiratory journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Rosella Centis, Marcos Abdo Arbex, Janwillem C Alffenaar, Jose A Caminero, Lia D'ambrosio, Mariechristine Payen, Valentina Alarcon Guizado, Saverio De LorenzoAbstract:No large study has ever evaluated the efficacy, safety and tolerability of meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/Clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/Clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/Clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p
Rosella Centis - One of the best experts on this subject based on the ideXlab platform.
-
comparison of effectiveness and safety of imipenem Clavulanate versus meropenem Clavulanate containing regimens in the treatment of mdr and xdr tb
European Respiratory Journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Lia Dambrosio, Rosella Centis, Marcos Abdo Arbex, Edith Alarcon Arrascue, Janwillem C Alffenaar, Jose A Caminero, Mina Gaga, Gina GualanoAbstract:No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/Clavulanate versus meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/Clavulanate versus meropenem/Clavulanate added to background regimens to treat MDR- and XDR-TB cases. 84 patients treated with imipenem/Clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p<0.0001) and higher XDR-TB prevalence (67.9% versus 49.0%, p=0.01) in comparison with 96 patients exposed to meropenem/Clavulanate-containing regimens. Patients were treated with imipenem/Clavulanate- and meropenem/Clavulanate-containing regimens for a median (interquartile range) of 187 (60–428) versus 85 (49–156) days, respectively. Statistically significant differences were observed on sputum smear and culture conversion rates (79.7% versus 94.8%, p=0.02 and 71.9% versus 94.8%, p<0.0001, respectively) and on success rates (59.7% versus 77.5%, p=0.03). Adverse events to imipenem/Clavulanate and meropenem/Clavulanate were reported in 5.4% and 6.5% of cases only. Our study suggests that meropenem/Clavulanate is more effective than imipenem/Clavulanate in treating MDR/XDR-TB patients. Meropenem/Clavulanate is safe and more effective than imipenem/Clavulanate in treating MDR and XDR-TB patients
-
Comparison of effectiveness and safety of imipenem/Clavulanate- versus meropenem/Clavulanate-containing regimens in the treatment of MDR- and XDR-TB
The European respiratory journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Rosella Centis, Marcos Abdo Arbex, Edith Alarcon Arrascue, Janwillem C Alffenaar, Jose A Caminero, Mina Gaga, Lia D'ambrosio, Gina GualanoAbstract:No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/Clavulanate versus meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/Clavulanate versus meropenem/Clavulanate added to background regimens to treat MDR- and XDR-TB cases. 84 patients treated with imipenem/Clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p
-
effectiveness and safety of meropenem Clavulanate containing regimens in the treatment of mdr and xdr tb
European Respiratory Journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Lia Dambrosio, Rosella Centis, Marcos Abdo Arbex, Janwillem C Alffenaar, Jose A Caminero, Mariechristine Payen, Valentina Alarcon Guizado, Saverio De LorenzoAbstract:No large study has ever evaluated the efficacy, safety and tolerability of meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/Clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/Clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/Clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p<0.0001) and the median (interquartile range (IQR)) number of antibiotic resistances was higher (8 (6–9) versus 5 (4–6)). Patients were treated with a meropenem/Clavulanate-containing regimen for a median (IQR) of 85 (49–156) days. No statistically significant differences were observed in the overall MDR-TB cohort and in the subgroups with and without the XDR-TB patients; in particular, sputum smear and culture conversion rates were similar in XDR-TB patients exposed to meropenem/Clavulanate-containing regimens (88.0% versus 100.0%, p=1.00 and 88.0% versus 100.0%, p=1.00, respectively). Only six cases reported adverse events attributable to meropenem/Clavulanate (four of them then restarting treatment). The nondifferent outcomes and bacteriological conversion rate observed in cases who were more severe than controls might imply that meropenem/Clavulanate could be active in treating MDR- and XDR-TB cases. Meropenem/Clavulanate is effective and safe to treat MDR- and XDR-TB in comparison with controls
-
Effectiveness and safety of meropenem/Clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
The European respiratory journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Rosella Centis, Marcos Abdo Arbex, Janwillem C Alffenaar, Jose A Caminero, Lia D'ambrosio, Mariechristine Payen, Valentina Alarcon Guizado, Saverio De LorenzoAbstract:No large study has ever evaluated the efficacy, safety and tolerability of meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/Clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/Clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/Clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p
Marcos Abdo Arbex - One of the best experts on this subject based on the ideXlab platform.
-
comparison of effectiveness and safety of imipenem Clavulanate versus meropenem Clavulanate containing regimens in the treatment of mdr and xdr tb
European Respiratory Journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Lia Dambrosio, Rosella Centis, Marcos Abdo Arbex, Edith Alarcon Arrascue, Janwillem C Alffenaar, Jose A Caminero, Mina Gaga, Gina GualanoAbstract:No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/Clavulanate versus meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/Clavulanate versus meropenem/Clavulanate added to background regimens to treat MDR- and XDR-TB cases. 84 patients treated with imipenem/Clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p<0.0001) and higher XDR-TB prevalence (67.9% versus 49.0%, p=0.01) in comparison with 96 patients exposed to meropenem/Clavulanate-containing regimens. Patients were treated with imipenem/Clavulanate- and meropenem/Clavulanate-containing regimens for a median (interquartile range) of 187 (60–428) versus 85 (49–156) days, respectively. Statistically significant differences were observed on sputum smear and culture conversion rates (79.7% versus 94.8%, p=0.02 and 71.9% versus 94.8%, p<0.0001, respectively) and on success rates (59.7% versus 77.5%, p=0.03). Adverse events to imipenem/Clavulanate and meropenem/Clavulanate were reported in 5.4% and 6.5% of cases only. Our study suggests that meropenem/Clavulanate is more effective than imipenem/Clavulanate in treating MDR/XDR-TB patients. Meropenem/Clavulanate is safe and more effective than imipenem/Clavulanate in treating MDR and XDR-TB patients
-
Comparison of effectiveness and safety of imipenem/Clavulanate- versus meropenem/Clavulanate-containing regimens in the treatment of MDR- and XDR-TB
The European respiratory journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Rosella Centis, Marcos Abdo Arbex, Edith Alarcon Arrascue, Janwillem C Alffenaar, Jose A Caminero, Mina Gaga, Lia D'ambrosio, Gina GualanoAbstract:No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/Clavulanate versus meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/Clavulanate versus meropenem/Clavulanate added to background regimens to treat MDR- and XDR-TB cases. 84 patients treated with imipenem/Clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p
-
effectiveness and safety of meropenem Clavulanate containing regimens in the treatment of mdr and xdr tb
European Respiratory Journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Lia Dambrosio, Rosella Centis, Marcos Abdo Arbex, Janwillem C Alffenaar, Jose A Caminero, Mariechristine Payen, Valentina Alarcon Guizado, Saverio De LorenzoAbstract:No large study has ever evaluated the efficacy, safety and tolerability of meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/Clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/Clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/Clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p<0.0001) and the median (interquartile range (IQR)) number of antibiotic resistances was higher (8 (6–9) versus 5 (4–6)). Patients were treated with a meropenem/Clavulanate-containing regimen for a median (IQR) of 85 (49–156) days. No statistically significant differences were observed in the overall MDR-TB cohort and in the subgroups with and without the XDR-TB patients; in particular, sputum smear and culture conversion rates were similar in XDR-TB patients exposed to meropenem/Clavulanate-containing regimens (88.0% versus 100.0%, p=1.00 and 88.0% versus 100.0%, p=1.00, respectively). Only six cases reported adverse events attributable to meropenem/Clavulanate (four of them then restarting treatment). The nondifferent outcomes and bacteriological conversion rate observed in cases who were more severe than controls might imply that meropenem/Clavulanate could be active in treating MDR- and XDR-TB cases. Meropenem/Clavulanate is effective and safe to treat MDR- and XDR-TB in comparison with controls
-
Effectiveness and safety of meropenem/Clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
The European respiratory journal, 2016Co-Authors: Simon Tiberi, Giovanni Sotgiu, Rosella Centis, Marcos Abdo Arbex, Janwillem C Alffenaar, Jose A Caminero, Lia D'ambrosio, Mariechristine Payen, Valentina Alarcon Guizado, Saverio De LorenzoAbstract:No large study has ever evaluated the efficacy, safety and tolerability of meropenem/Clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/Clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/Clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/Clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p